29 news items
From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data
ABBV
AZN
BMY
19 Jun 24
that the combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab yielded tumor response rates
From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data
ABBV
AZN
BMY
19 Jun 24
that the combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab yielded tumor response rates
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
ABBV
18 Jun 24
and not greater than baseline, RBS of 0 and endoscopic subscore ≤1 without friability) at week 12. Secondary endpoints include clinical response (decrease
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
ABBV
COP
MRO
17 Jun 24
response
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
ABBV
14 Jun 24
in any way with Tutanota, its offer, or the offer documents. AbbVie recommends that AbbVie shareholders do not tender their shares in response
ymu8dohed acm6krz339kilx9rv5lcjcucvu2qu1
ABBV
11 Jun 24
with the response
23eaa4tlb2y1k6yybupzgim1byzw dxoghuboyzjtxbn8v6iy5
ABBV
ABOS
ALXO
6 Jun 24
on Jun 5 in response to the encouraging news. Year to date, the stock has jumped 23.5% against the industry's 5.6% decline
xmuktvwrq5x5tr023gcn6taj31yz0gvgsjgpycds2jebfdzqnn3
ABBV
6 Jun 24
).
The study met its primary endpoint with an objective response rate (ORR) of 51.9%.
In addition, the median duration of response (DOR), a key
znyq8qk4p345gosb1mpe4q5 ascf6ox0b2ekrjcx4rxe
ABBV
6 Jun 24
PICCOLO trial met its primary endpoint of objective response rate (ORR)Data from the study will be presented at a future
sjvniaj2v6gw6lno440u3 f6qjebpix0nq1aljmorxhmdr4pnkag0bjd
ABBV
6 Jun 24
met its primary endpoint of objective response rate (ORR)Data
2r6lihksw8sl9s2y
ABBV
6 Jun 24
and supervisors perceive their migraine attacks as an excuse to dismiss responsibilities at work.4,5
qe3q9nr88aoob4xg02kyp0e3zxgzo1nnio4vrf5
ABBV
5 Jun 24
.
The dual primary end points are progression-free survival and overall response rate. Secondary end points include overall survival, complete response (CR
eak5zuqwl3l 3dvw5f
ABBV
5 Jun 24
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts
p29052n4yzixip4vtv8ilk ieq8v5gmh7ka2k1dy
ABBV
4 Jun 24
polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one
ez34n 0lg
ABBV
4 Jun 24
establishedTell your specialist if you are on therapy used to decrease the body's immune response
wwb6tpu8sj8ff00b6orv 5xpbk2v1wui5ugmnj0e9qw3d8tayug1leb
ABBV
ALXO
ANVS
3 Jun 24
UC patients who have had an inadequate response, lost response, or were intolerant to either conventional or biologic therapy. The recommended
zyki6zvvrtw63gblywqoir hq4rp3b3lcd3mm6ps601qs
ABBV
31 May 24
an inadequate response, lost response, or were intolerant to either conventional or biologic therapy. The recommended induction dose is 1200 mg intravenous
bbh40zq33ptqdkz cr7nx6xab58d0xzucgmj4kukrxfzauoxa
ABBV
CYTO
ONCY
24 May 24
expansion and tumor response. The ASCO annual meeting will take place from May 31 – June 4, 2024, in Chicago, Illinois. "The two
4lr3 wmvp
ABBV
17 May 24
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts
cqptru 42tm8x540xnwftjtix7d7ux20yqgdufus8lfzmey2f
ABBV
17 May 24
Ulcerative Colitis Who Did Not Achieve Clinical Response to Initial 12-Week Induction Therapy